FDA Update: Tirzepatide Expanding Approved Indications

Important update from FDA clinical trials database. Tirzepatide is showing promising results in Phase III trials for additional indications beyond diabetes and weight loss. New potential indications: - Non-alcoholic fatty liver disease (NAFLD) - Sleep apnea - Cardiovascular risk reduction The NAFLD data is particularly interesting - 74% of participants showed significant liver fat reduction. Source: https://clinicaltrials.gov This could expand access and insurance coverage significantly. Anyone following these developments closely?